ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "systemic sclerosis and tocilizumab"

  • Abstract Number: 126 • 2018 ACR/ARHP Annual Meeting

    Direct Interaction between Autoreactive B Cells and Endothelial Colony Forming Cells Induces Cytokine Production from B Cells through B Cell Receptor and IL-6-JAK2-STAT3 Signaling Pathway, Suppressing Proliferation of Endothelial Colony Forming Cells in Systemic Sclerosis

    Takemichi Fukasawa1, Ayumi Yoshizaki1, Satoshi Ebata1, Kouki Nakamura1, Yoshihide Asano1, Yutaka Kazoe2, Kazuma Mawatari2, Takehiko Kitamori2 and Shinichi Sato1, 1Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 2Department of Applied Chemistry, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan

    Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disorder that is characterized by fibrosis and vascular damage in the skin and other visceral organs, with…
  • Abstract Number: 1740 • 2018 ACR/ARHP Annual Meeting

    Effectiveness and Safety of Tocilizumab for the Treatment of Refractory Systemic Sclerosis Associated Interstitial Lung Disease: A Case Series

    Judit Lluch1, Ivan Castellvi2, J Alegre3, Pablo Juárez1, Joan Miquel Nolla1 and Francisco Javier Narváez4, 1Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 2Rheumatology, Hospital Santa Creu i San Pau, Barcelona, Spain, 3Rheumatology, Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, 4Rheumatology Department, Hospital Universitario de Bellvitge, Idibell, Barcelona, Spain

    Background/Purpose: To evaluate the efficacy and safety of TCZ as as a rescue therapy in patients with refractory scleroderma-associated interstitial lung disease (SSc-ILD). Methods: We…
  • Abstract Number: 969 • 2016 ACR/ARHP Annual Meeting

    Safety and Efficacy of Subcutaneous Tocilizumab in Early Systemic Sclerosis: Results from the Open-Label Period of a Phase 2 Randomized, Controlled Trial

    Dinesh Khanna1, Christopher Denton2, Helen Spotswood3, Angelika Jahreis4, Jacob M. van Laar5, Laura Burke6, Celia J. F. Lin4, Janet E. Pope7, Yannick Allanore8, Ulf Müller-Ladner9, Jeffrey Siegel6, Daniel E. Furst10 and faSScinate Clinical Trial Investigators, 1University of Michigan, Ann Arbor, MI, 2Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, 3Roche Products Ltd., Welwyn Garden City, CA, United Kingdom, 4Genentech, South San Francisco, CA, 5University Medical Center Utrecht, Utrecht, Netherlands, 6Roche Products Ltd., Welwyn Garden City, United Kingdom, 7University of Western Ontario, St Joseph's Health Care, London, ON, Canada, 8Rheumatology, Paris Descartes University, Paris, France, 9Justus-Liebig-University Giessen, Department of Internal Medicine and Rheumatology, Kerckhoff-Klinik, Bad Nauheim, Germany, Bad-Nauheim, Germany, 10University of California, Los Angeles, Los Angeles, CA

    Background/Purpose:  Systemic sclerosis (SSc) is a debilitating disease with few treatment options. Interleukin-6 (IL-6) appears to play a role in SSc pathogenesis (J Rheumatol 1998;25:308;…
  • Abstract Number: 2151 • 2015 ACR/ARHP Annual Meeting

    Inhibition of Myeloid-Associated Gene Expression in Skin Biopsy Samples of Systemic Sclerosis Patients Treated with Tocilizumab

    Thierry Sornasse1, Haiyin Chen1, Lisa Rice2, Giuseppina Stifano2, Angelika Jahreis1, Jeffrey Siegel1 and Robert Lafyatis2, 1Genentech, South San Francisco, CA, 2Boston University School of Medicine, Boston, MA

    Background/Purpose: Systemic sclerosis (SSc) is a progressive, debilitating disease with limited treatment options. IL-6 has been implicated in disease pathogenesis. Tocilizumab (TCZ), an IL-6Rα inhibitor,…
  • Abstract Number: 874 • 2014 ACR/ARHP Annual Meeting

    Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis: Week 24 Data from a Phase 2/3 Trial

    Dinesh Khanna1, Christopher P. Denton2, Jacob M. van Laar3, Angelika Jahreis4, Sabrina Cheng4, Helen Spotswood5, Jeffrey Siegel4 and Daniel E. Furst on behalf of FaSScinate Clinical Trial in Patients With SS6, 1University of Michigan Health System, Ann Arbor, MI, 2University College London Medical School, London, United Kingdom, 3University Medical Center Utrecht, Utrecht, Netherlands, 4Genentech, South San Francisco, CA, 5Roche Products Ltd., Welwyn Garden City, United Kingdom, 6University of California, Los Angeles, CA

    Background/Purpose: Systemic sclerosis (SSc) is a progressive, debilitating disease with limited treatment options. IL-6 has been implicated in disease pathogenesis.1,2 IL-6 receptor inhibition prevented and…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.